TICKERNERD
Menu
ACIUACIUHealthcare · Biotechnology

ACIU Stock Forecast: AC Immune SA Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.76
+2.60% on the day

The 4 Wall Street analysts covering AC Immune SA hold a median 12-month price target of $8.38 — +203.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$274.4M
Ticker Nerd rank
35 / 100
Median analyst target
$8.38
Analysts covering
4
Revenue$15.1M+1057.2% y/y
Operating income$1.2M
Net income$1.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.8%
1M
+8.7%
YTD
−12.1%
1Y
+16.0%
From 52W high
−30.8%
From 52W low
+30.2%
$2.12
$3.99
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACIU stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AC Immune SA on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
35 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
64
Volatility
62
Issuance
60
Momentum
52
Revisions
52
Value
41
Growth
38
Accruals
33
Quality
16

Size (64): Smaller than most of the companies we track.

Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ACIU stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACIU, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26ACIUHigh $11.75Median $8.38Low $5.30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $5.30Median $8.38High $11.75

The green dot is the last close — the median target sits +203.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Aug 2026BTIGReiteratesBuy$8.00
5 Aug 2026BTIGReiteratesBuy$8.00
5 Aug 2026BTIGReiteratesBuy—
4 May 2026BTIGReiteratesBuy$8.00
4 May 2026BTIGReiteratesBuy—
16 Mar 2026BTIGReiteratesBuy—
4 Nov 2025BTIGReiteratesBuy—
8 Sept 2025BTIGReiteratesBuy—
1 May 2025HC Wainwright & Co.MaintainsBuy—
3 Apr 2025HC Wainwright & Co.ReiteratesBuy—
3 Apr 2025HC Wainwright& Co.ReiteratesBuy—
14 Mar 2025HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
6 Nov 2024HC Wainwright & Co.ReiteratesBuy—
18 Sept 2024HC Wainwright & Co.ReiteratesBuy—
31 May 2024BTIGInitiatesBuy—
15 Mar 2024HC Wainwright & Co.ReiteratesBuy—
13 Nov 2023HC Wainwright & Co.ReiteratesBuy—
7 Aug 2023HC Wainwright & Co.ReiteratesBuy—
28 June 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACIU appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ACIU vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, AC Immune SA returned +16.0% against +17.5% for the S&P 500, dividends included.

ACIU vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Oct 25Jan 26Apr 26Jul 26ACIUS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ACIU analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

AC Immune SA (ACIU) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.9×

Cheaper than 88% of US stocks

Price / sales
15.7×

Cheaper than 10% of US stocks

Price / book
6.3×

Cheaper than 16% of US stocks

EV / EBITDA
−4.8×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
1057.2%

Higher than 99% of US stocks

Earnings growth (YoY)
1057.2%

Higher than 98% of US stocks

Gross margin
—
Operating margin
7.9%

Higher than 60% of US stocks

Net margin
−246.5%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−78.5%

Higher than 16% of US stocks

Return on assets
−16.0%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

AC Immune SA (ACIU) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • AC Immune SA has a market value of $274.4M and an enterprise value of $248.9M.

  • Revenue in the twelve months to 30 June 2026: $17.5M. The latest quarter grew 1057.2% year on year.

  • Net income over the same four quarters: −$43.2M, a −246.5% net margin.

  • Shares outstanding: 99.4M.

  • Trailing P/E: −3.9×; forward P/E: 4.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • AC Immune SA employs 90 people — $195K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

ACIU vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ACIUAC Immune SA$274.4M
35
IMRXImmuneering Corp.$275.7M
47
STROSutro Biopharma, Inc.$276.3M
73
FATEFate Therapeutics, Inc.$268.6M
94
ALXOALX Oncology Holdings, Inc.$268.3M
62
PYXSPyxis Oncology, Inc.$267.7M
80
CAMPCAMP4 Therapeutics Corp.$266.7M
65

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AC Immune SA — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ACIU news & analysis

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

GlobeNewsWire · 20 Aug 2026positive

AC Immune announced positive interim Phase 1 results from a first-in-human clinical study of ACI-19764, an NLRP3 inhibitor that targets inflammation. The preliminary Phase 1 data were characterized as positive.

Why it matters — This marks early clinical progress for a new pipeline candidate, ACI-19764, that broadens AC Immune's focus into inflammation alongside its existing programmes.

AC Immune (ACIU) Beats Q2 Earnings and Revenue Estimates

Zacks Investment Research · 5 Aug 2026positive

AC Immune reported Q2 earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share and improving from a loss of $0.25 per share a year ago. The company also beat revenue estimates for the quarter, according to the headline.

Why it matters — ACIU watchers would care because the company exceeded analyst expectations for the quarter, marking a year-over-year improvement in results.

AC Immune First Half 2026 Financial and Corporate Update

GlobeNewsWire · 5 Aug 2026positive

AC Immune issued its first-half 2026 financial and corporate update, reporting CHF 75.4 million in cash at June 30, 2026, funding into Q4 2027. The company highlighted progress across wholly-owned programs including the Phase 2 VacSYn trial of ACI-7104 in Parkinson's disease, supported by a $4 million grant, the Morphomer Tau program with Lilly, and a $12 million milestone payment from Takeda triggered by initiation of the AD4 cohort in the ABATE trial, with further clinical results anticipated in H2 2026.

Why it matters — ACIU watchers would care because the update confirms near-term clinical catalysts in wholly-owned programs alongside milestone payments and cash visibility extending into Q4 2027.

FAQ

Frequently asked questions about ACIU stock

What is the ACIU stock price forecast for 2026-2027?

The 4 Wall Street analysts covering AC Immune SA have a median 12-month price target of $8.38, with estimates ranging from $5.3 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACIU stock a buy right now?

Of the 4 analysts covering AC Immune SA, 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AC Immune SA 35 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACIU?

As at 12 Sept 2026, AC Immune SA ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (64 of 100).

Will ACIU stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +203.5% from the last close, and Ticker Nerd's factor model ranks AC Immune SA 35 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACIU stock forecast for 2030?

No analyst covering AC Immune SA publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACIU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5.3 to $12 over the next 12 months.

How has ACIU stock performed over the past year?

AC Immune SA returned +16.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AC Immune SA do?

AC Immune SA is a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases. AC Immune SA develops therapeutic and diagnostic products designed to address disorders linked to protein misfolding, with a current emphasis on Alzheimer’s disease, Parkinson’s disease, ALS, and selected rare neurodegenerative conditions.

What is the latest news on ACIU?

The most recent item we track (GlobeNewsWire, 20 Aug 2026): "AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764". AC Immune announced positive interim Phase 1 results from a first-in-human clinical study of ACI-19764, an NLRP3 inhibitor that targets inflammation. The preliminary Phase 1 data were characterized as positive.

Company

About AC Immune SA.

AC Immune SA is a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases. AC Immune SA develops therapeutic and diagnostic products designed to address disorders linked to protein misfolding, with a current emphasis on Alzheimer’s disease, Parkinson’s disease, ALS, and selected rare neurodegenerative conditions. Its work centers on proprietary technology platforms that support the discovery of antibodies, small molecules, vaccines, and imaging agents intended for early detection, treatment, and prevention. The company’s pipeline spans both therapeutic and diagnostic programs, reflecting a dual approach to understanding disease biology and creating targeted interventions. AC Immune SA also collaborates with pharmaceutical and research partners to advance its programs across neurodegenerative markets. Headquartered in Lausanne, Switzerland, AC Immune SA plays a specialized role in the biotechnology sector by developing tools and treatments aimed at some of the most complex and underserved diseases of the nervous system.

CEO Dr. Martin Zugel M.D., Ph.D. · 90 employees · Switzerland · https://www.acimmune.com